A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin in Patients With Moderate to Severe Glabellar Lines
Latest Information Update: 07 Jul 2023
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Sponsors Huons
Most Recent Events
- 02 Jul 2023 Status changed from active, no longer recruiting to completed.
- 14 Feb 2023 Planned End Date changed from 1 Aug 2022 to 1 May 2023.
- 14 Feb 2023 Status changed from not yet recruiting to active, no longer recruiting.